Carlyle and Brighton Park Capital obtain minority stakes in Indegene for $200m

Medical Devices

Carlyle and Brighton Park Capital will obtain minority stakes in Indegene for two-hundred million dollars. The deal is subject to customary regulatory approvals and consists of a secondary sale from Indigene's current shareholders and a primary investment.

Indegene plans to use Carlyle and Brighton Park's primary investment to accelerate its global expansion plans and M&A.

“Carlyle and Brighton Park Capital obtain minority stakes in Indegene for $200m.“

CEO and Co-Founder, Indegene, Manish Gupta, stated: “We are excited about our partnership with Carlyle and Brighton Park as their collective strengths will bring significant value to Indegene as we build on the deep domain knowledge and vertical technology we have developed over the past twenty years. Carlyle’s commitment to the healthcare sector with their global network and deep pharmaceutical expertise, coupled with Brighton Park’s deep experience in the technology sector and nuanced understanding of our space, makes the 2 firms the ideal partners to support our company’s continued growth.”

Managing Director, Carlyle Asia advisory team, Neeraj Bharadwaj, stated: “We have been impressed by the strong entrepreneurial energy of the management team at Indegene and their technology-led, data-driven, differentiated global delivery model, as well as by their ability to scale relationships with global healthcare enterprises. We believe this puts Indegene in a strong position to benefit from the significant growth drivers we are seeing in the healthcare space. We look forward to leveraging our global healthcare network and capabilities to help the company further strengthen and expand its portfolio while deepening relationships with its global client base.”

See all the latest jobs in Medical Devices
Return to news